Hyderabad: Indian Immunological Limited (IIL) in the city and the pharmaceutical company Bharat Biotech have reached an agreement that IIL will need the substance needed to manufacture the Covaxin vaccine, COVID-19 virus. According to the agreement, IIL will supply the drug needed for the manufacture of the Covaxin vaccine to Bharat Biotech, a press release from the center said on Friday.
IIL, a facility under the National Dairy Development Council, received funds under the mission of the central government COVID Suraksha program to COVID-19 vaccine production in India. Managing Director of Indian Immunological Limited, Dr K. Anand Kumar, said that IIL intends to start production of the medicine needed for Covaxin from June 15, and that it will limit the first group to Bharat Biotech, which by July is limited.
The development comes after the central government decided to support companies (or businesses) in the public sector with grants under the Mission COVID Suraksha. One such PSU is the Hyderabad-based Indian Immunological Limited (IIL), which is a facility under the National Dairy Development Council.
The statement that Indian immunological drugs are expected to produce the Covaxin drug for about 10-15 million doses per month, Dr. Anand Kumar said that it will initially be 2-3 million doses and later will be suspended to 6-7 million per month. the year.
Dr. Kumar added that they are transforming the IIL Karakapatla manufacturing unit near Hyderabad into a ‘Bio Safety’ level -3 (BSL3) for the manufacture of the drug Covaxin. The IIL is also working on another COVID-19 vaccine and the animal trials are currently underway and are expected to come out by next year for human vaccination.
Under Atmanirbhar Bharat 3.0 Mission, the COVID The Suraksha program has been announced by the Government of India (GoI) to accelerate the development and production of indigenous COVID-19 Vaccines. It is implemented by the Department of Biotechnology. The Indian Immunologicals Limited (IIL), Hyderabad, received a grant of Rs. 60 points to improve production capabilities.
Source: The Siasat Daily